Pfizer offers several methods of financial support to help your patients pay for PRISTIQ

Help your patients save up to $180 a year*

With the PRISTIQ Savings Card your eligible patients can save up to $15 on each prescription and up to $180 a year off their prescription costs.

*Terms and conditions apply. No membership fees apply. See below for full details. The PRISTIQ Savings Card is not health insurance. The card will only be accepted at participating pharmacies.

Call your Pfizer representative to receive cards for your practice.

Patients can request a PRISTIQ Savings Card directly by calling 1-800-841-3018 or online at PRISTIQ.com.

Pfizer Helpful Answers — Patient Assistance Programs

Pfizer Helpful Answers is a family of assistance programs for uninsured and underinsured patients who need help getting their Pfizer medicines. For additional information on the family of Pfizer Helpful Answer programs, visit Pfizer Helpful Answers.

Connection to Care

Your eligible uninsured patients can receive a free 90-day supply of Pfizer medications through your office.

To help a patient apply to Connection to Care:

• Download an application Here or request one by calling (866) 706-2400
• You and your patient must submit a completed application along with proof of income

To be eligible for Connection to Care, patients must:

• Either have no prescription coverage or qualify for hardship assistance
• Meet the household income guidelines for the program
• Reside in the United States, the US Virgin Islands, or Puerto Rico

For more information, visit Connection to Care

Pfizer Pfriends^®

Offering savings to patients without prescription drug coverage, regardless of their age or income.

To apply for the Pfizer Pfriends Program, patients must:

• Fill out an application. You can download an application to give to your patients Here or request one by calling (866) 706-2400
• Complete the application, which covers the entire family. Proof of income is not required

To be eligible for the Pfizer Pfriends Program, patients must:

• Have no prescription coverage
• Reside in the United States, the US Virgin Islands, or Puerto Rico

For more information, visit Pfizer Pfriends

PRISTIQ Savings Card Terms and Conditions

• The Card is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare or other federal or state health care programs including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico (formerly known as "La Reforma de Salud")
• The Card is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or other health or pharmacy benefit programs which reimburse you for the entire cost of your prescription drugs
• You will save either $15 or the amount of your co-pay/out-of-pocket cost, whichever is less. Card can only be used for up to 12 prescriptions a year
• You must deduct the value received under this program from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf
• The Card is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third-party insurance, or where otherwise prohibited by law
• Cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription
• The Card will be accepted only at participating pharmacies
• This Card is not health insurance
• Offer good only in the U.S. and Puerto Rico
• The Card is limited to one person during this offering period and is not transferable
• Pfizer reserves the right to rescind, revoke, or amend the program without notice
• No membership fees
• Card and program expire 12/31/12

Next: Patient Support & Education

Please see Full Prescribing Information including Boxed Warning & Medication Guide

PRISTIQ Extended-Release Tablets are indicated for the treatment of major depressive disorder in adults.

Important Safety Information for PRISTIQ

Contraindications

• PRISTIQ is contraindicated in patients with a known hypersensitivity to PRISTIQ or venlafaxine.
• PRISTIQ must not be used concomitantly with an MAOI or within 14 days of stopping an MAOI.  Allow 7 days after stopping PRISTIQ before starting an MAOI.

Warnings and Precautions

• All patients treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of treatment and when changing the dose. Consider changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or includes symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania, or suicidality that are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Families and caregivers of patients being treated with antidepressants should be alerted about the need to monitor patients. 
• Development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome-like reactions have been reported with SNRIs and SSRIs alone, including PRISTIQ treatment, but particularly with concomitant use of serotonergic drugs, including triptans, with drugs that impair the metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. If concomitant use with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Concomitant use of PRISTIQ with serotonin precursors is not recommended.
• Patients receiving PRISTIQ should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies. Pre-existing hypertension should be controlled before starting PRISTIQ. Caution should be exercised in treating patients with pre-existing hypertension or other underlying conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported. For patients who experience a sustained increase in blood pressure, either dose reduction or discontinuation should be considered.
• SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, NSAIDs, warfarin, and other anticoagulants may add to this risk.
• Mydriasis has been reported in association with PRISTIQ; therefore, patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma (angle-closure glaucoma) should be monitored.
• PRISTIQ is not approved for use in bipolar depression. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine the risk of bipolar disorder.
• As with all antidepressants, PRISTIQ should be used cautiously in patients with a history or family history of mania or hypomania, or with a history of seizure disorder.
• Caution is advised in administering PRISTIQ to patients with cardiovascular, cerebrovascular, or lipid metabolism disorders. Increases in blood pressure and small increases in heart rate were observed in clinical studies with PRISTIQ. PRISTIQ has not been evaluated systematically in patients with a recent history of myocardial infarction, unstable heart disease, uncontrolled hypertension, or cerebrovascular disease.
• Dose-related elevations in fasting serum total cholesterol, LDL (low density lipoprotein) cholesterol, and triglycerides were observed in clinical studies. Measurement of serum lipids should be considered during PRISTIQ treatment.
• On discontinuation, adverse events, some of which may be serious, have been reported with PRISTIQ and other SSRIs and SNRIs. Abrupt discontinuation of PRISTIQ has been associated with the appearance of new symptoms. Patients should be monitored for symptoms when discontinuing treatment. A gradual reduction in dose rather than abrupt cessation is recommended whenever possible.
• The recommended dose in patients with severe renal impairment or end-stage renal disease (ESRD) is 50 mg every other day. The dose should not be escalated in patients with moderate or severe renal impairment or ESRD.
• Products containing desvenlafaxine and products containing venlafaxine should not be used concomitantly with PRISTIQ.
• Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. Discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia.
• Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported.

Adverse Reactions

• The most commonly observed adverse reactions in patients taking PRISTIQ vs placebo for MDD in short-term fixed-dose premarketing studies (incidence ≥5% and at least twice the rate of placebo in the 50-mg dose group) were nausea (22% vs 10%), dizziness (13% vs 5%), hyperhidrosis (10% vs 4%), constipation (9% vs 4%), and decreased appetite (5% vs 2%).

PQP00126